Microbial context predicts SARS-CoV-2 prevalence in patients and the hospital built environment
Synergistic effects of bacteria on viral stability and transmission are widely documented but remain unclear in the context of SARS-CoV-2. We collected 972 samples from hospitalized ICU patients with coronavirus disease 2019 (COVID-19), their health care providers, and hospital surfaces before, during, and after admission. We screened for SARS-CoV-2 using RT-qPCR, characterized microbial communities using 16S rRNA gene amplicon sequencing, and contextualized the massive microbial diversity in this dataset in a meta-analysis of over 20,000 samples. Sixteen percent of surfaces from COVID-19 patient rooms were positive, with the highest prevalence in floor samples next to patient beds (39%) and directly outside their rooms (29%). Although bed rail samples increasingly resembled the patient microbiome throughout their stay, SARS-CoV-2 was less frequently detected there (11%). Despite surface contamination in almost all patient rooms, no health care workers providing COVID-19 patient care contracted the disease. SARS-CoV-2 positive samples had higher bacterial phylogenetic diversity across human and surface samples, and higher biomass in floor samples. 16S microbial community profiles allowed for high classifier accuracy for SARS-CoV-2 status in not only nares, but also forehead, stool and floor samples. Across these distinct microbial profiles, a single amplicon sequence variant from the genus Rothia was highly predictive of SARS-CoV-2 across sample types, and had higher prevalence in positive surface and human samples, even when comparing to samples from patients in another intensive care unit prior to the COVID-19 pandemic. These results suggest that bacterial communities contribute to viral prevalence both in the host and hospital environment.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2020 |
|---|---|
| Enthalten in: |
medRxiv : the preprint server for health sciences - (2020) vom: 22. Nov. |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 04.11.2023 published: Electronic UpdateIn: Microbiome. 2021 Jun 8;9(1):132. - PMID 34103074 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1101/2020.11.19.20234229 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318027348 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318027348 | ||
| 003 | DE-627 | ||
| 005 | 20231225164510.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2020.11.19.20234229 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1060.xml |
| 035 | |a (DE-627)NLM318027348 | ||
| 035 | |a (NLM)33236030 | ||
| 035 | |a (PII)2020.11.19.20234229 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Marotz, Clarisse |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Microbial context predicts SARS-CoV-2 prevalence in patients and the hospital built environment |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 04.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a UpdateIn: Microbiome. 2021 Jun 8;9(1):132. - PMID 34103074 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Synergistic effects of bacteria on viral stability and transmission are widely documented but remain unclear in the context of SARS-CoV-2. We collected 972 samples from hospitalized ICU patients with coronavirus disease 2019 (COVID-19), their health care providers, and hospital surfaces before, during, and after admission. We screened for SARS-CoV-2 using RT-qPCR, characterized microbial communities using 16S rRNA gene amplicon sequencing, and contextualized the massive microbial diversity in this dataset in a meta-analysis of over 20,000 samples. Sixteen percent of surfaces from COVID-19 patient rooms were positive, with the highest prevalence in floor samples next to patient beds (39%) and directly outside their rooms (29%). Although bed rail samples increasingly resembled the patient microbiome throughout their stay, SARS-CoV-2 was less frequently detected there (11%). Despite surface contamination in almost all patient rooms, no health care workers providing COVID-19 patient care contracted the disease. SARS-CoV-2 positive samples had higher bacterial phylogenetic diversity across human and surface samples, and higher biomass in floor samples. 16S microbial community profiles allowed for high classifier accuracy for SARS-CoV-2 status in not only nares, but also forehead, stool and floor samples. Across these distinct microbial profiles, a single amplicon sequence variant from the genus Rothia was highly predictive of SARS-CoV-2 across sample types, and had higher prevalence in positive surface and human samples, even when comparing to samples from patients in another intensive care unit prior to the COVID-19 pandemic. These results suggest that bacterial communities contribute to viral prevalence both in the host and hospital environment | ||
| 650 | 4 | |a Preprint | |
| 700 | 1 | |a Belda-Ferre, Pedro |e verfasserin |4 aut | |
| 700 | 1 | |a Ali, Farhana |e verfasserin |4 aut | |
| 700 | 1 | |a Das, Promi |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Shi |e verfasserin |4 aut | |
| 700 | 1 | |a Cantrell, Kalen |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Lingjing |e verfasserin |4 aut | |
| 700 | 1 | |a Martino, Cameron |e verfasserin |4 aut | |
| 700 | 1 | |a Diner, Rachel E |e verfasserin |4 aut | |
| 700 | 1 | |a Rahman, Gibraan |e verfasserin |4 aut | |
| 700 | 1 | |a McDonald, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Armstrong, George |e verfasserin |4 aut | |
| 700 | 1 | |a Kodera, Sho |e verfasserin |4 aut | |
| 700 | 1 | |a Donato, Sonya |e verfasserin |4 aut | |
| 700 | 1 | |a Ecklu-Mensah, Gertrude |e verfasserin |4 aut | |
| 700 | 1 | |a Gottel, Neil |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia, Mariana C Salas |e verfasserin |4 aut | |
| 700 | 1 | |a Chiang, Leslie Y |e verfasserin |4 aut | |
| 700 | 1 | |a Salido, Rodolfo A |e verfasserin |4 aut | |
| 700 | 1 | |a Shaffer, Justin P |e verfasserin |4 aut | |
| 700 | 1 | |a Bryant, MacKenzie |e verfasserin |4 aut | |
| 700 | 1 | |a Sanders, Karenina |e verfasserin |4 aut | |
| 700 | 1 | |a Humphrey, Greg |e verfasserin |4 aut | |
| 700 | 1 | |a Ackermann, Gail |e verfasserin |4 aut | |
| 700 | 1 | |a Haiminen, Niina |e verfasserin |4 aut | |
| 700 | 1 | |a Beck, Kristen L |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Ho-Cheol |e verfasserin |4 aut | |
| 700 | 1 | |a Carrieri, Anna Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Parida, Laxmi |e verfasserin |4 aut | |
| 700 | 1 | |a Vázquez-Baeza, Yoshiki |e verfasserin |4 aut | |
| 700 | 1 | |a Torriani, Francesca J |e verfasserin |4 aut | |
| 700 | 1 | |a Knight, Rob |e verfasserin |4 aut | |
| 700 | 1 | |a Gilbert, Jack A |e verfasserin |4 aut | |
| 700 | 1 | |a Sweeney, Daniel A |e verfasserin |4 aut | |
| 700 | 1 | |a Allard, Sarah M |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t medRxiv : the preprint server for health sciences |d 2020 |g (2020) vom: 22. Nov. |w (DE-627)NLM310900166 |7 nnns |
| 773 | 1 | 8 | |g year:2020 |g day:22 |g month:11 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2020.11.19.20234229 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2020 |b 22 |c 11 | ||